Bicara Therapeutics (BCAX) Accumulated Expenses (2023 - 2026)

Bicara Therapeutics has reported Accumulated Expenses for 4 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 89.42% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 89.42% YoY), and the FY2025 full-year result was $1.1 million, down 91.14% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.3 million, up from $1.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $12.9 million in Q4 2024, with the low at $700000.0 in Q3 2025.
• Historically, Accumulated Expenses has averaged $5.4 million across 4 years, with a median of $3.8 million in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 59.88% — and 2025, when it slumped 91.14%.
• Bicara Therapeutics' Accumulated Expenses stood at $8.1 million in 2023, then jumped by 59.88% to $12.9 million in 2024, then tumbled by 91.14% to $1.1 million in 2025, then advanced by 13.94% to $1.3 million in 2026.
• The last three Accumulated Expenses figures came in at $1.3 million (Q1 2026), $1.1 million (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.